Multiple mutations in heterogeneous miltefosine-resistant leishmania major population as determined by whole genome sequencing

PLoS Neglected Tropical Diseases

Volumn 6, Issue 2, 2012, Pages

  Coelho, Adriano C ^a   Boisvert, Sébastien ^a   Mukherjee, Angana ^a   Leprohon, Philippe ^a   Corbeil, Jacques ^a   Ouellette, Marc ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALPHA ADAPTIN; MILTEFOSINE; PHOSPHOLIPID; PYRIDOXAL KINASE; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; MUTANT PROTEIN; PHOSPHORYLCHOLINE; PROTOZOAL PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE DISRUPTION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENETIC TRANSFECTION; GENOTYPE; LEISHMANIA MAJOR; LEISHMANIASIS; MUTANT; NONHUMAN; PHENOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; PROMASTIGOTE; SOUTHERN BLOTTING; ANIMAL; DNA SEQUENCE; DRUG EFFECT; DRUG RESISTANCE; GENETIC SELECTION; GENETICS; GENOME; HUMAN; ISOLATION AND PURIFICATION; MISSENSE MUTATION;

ANIMALS; ANTIPROTOZOAL AGENTS; DRUG RESISTANCE; GENOME, PROTOZOAN; HUMANS; LEISHMANIA MAJOR; MUTANT PROTEINS; MUTATION, MISSENSE; PHOSPHORYLCHOLINE; PROTOZOAN PROTEINS; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 84857860666     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001512     Document Type: Article

References (63)

1. Herwaldt BL, (1999) Leishmaniasis. Lancet 354: 1191-1199.
2. Croft SL, Sundar S, Fairlamb AH, (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111-126.
3. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, et al. (1999) Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341: 1795-1800.
4. Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, et al. (2001) Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33: E57-61.
5. Sundar S, Jha TK, Thakur CP, Bhattacharya SK, Rai M, (2006) Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg 100 (Suppl 1): S26-33.
6. Lux H, Heise N, Klenner T, Hart D, Opperdoes FR, (2000) Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol Biochem Parasitol 111: 1-14.
7. Paris C, Loiseau PM, Bories C, Breard J, (2004) Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 48: 852-859.
8. Tewari R, Sharma V, Koul N, Sen E, (2008) Involvement of miltefosine-mediated ERK activation in glioma cell apoptosis through Fas regulation. J Neurochem 107: 616-627.
9. Perez-Victoria FJ, Gamarro F, Ouellette M, Castanys S, (2003) Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J Biol Chem 278: 49965-49971.
10. Grant AM, Hanson PK, Malone L, Nichols JW, (2001) NBD-labeled phosphatidylcholine and phosphatidylethanolamine are internalized by transbilayer transport across the yeast plasma membrane. Traffic 2: 37-50.
11. Hanson PK, Malone L, Birchmore JL, Nichols JW, (2003) Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine. J Biol Chem 278: 36041-36050.
12. Perez-Victoria FJ, Sanchez-Canete MP, Castanys S, Gamarro F, (2006) Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. J Biol Chem 281: 23766-23775.
13. Escobar P, Matu S, Marques C, Croft SL, (2002) Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop 81: 151-157.
14. Yardley V, Croft SL, De Doncker S, Dujardin JC, Koirala S, et al. (2005) The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 73: 272-275.
15. Sanchez-Canete MP, Carvalho L, Perez-Victoria FJ, Gamarro F, Castanys S, (2009) Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug. Antimicrob Agents Chemother 53: 1305-1313.
16. Mollinedo F, Fernandez-Luna JL, Gajate C, Martin-Martin B, Benito A, et al. (1997) Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Cancer Res 57: 1320-1328.
17. Zoeller RA, Layne MD, Modest EJ, (1995) Animal cell mutants unable to take up biologically active glycerophospholipids. J Lipid Res 36: 1866-1875.
18. Perez-Victoria FJ, Castanys S, Gamarro F, (2003) Leishmania donovani Resistance to Miltefosine Involves a Defective Inward Translocation of the Drug. Antimicrob Agents Chemother 47: 2397-2403.
19. Rakotomanga M, Saint-Pierre-Chazalet M, Loiseau PM, (2005) Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions. Antimicrob Agents Chemother 49: 2677-2686.
20. Seifert K, Perez-Victoria FJ, Stettler M, Sanchez-Canete MP, Castanys S, et al. (2007) Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents 30: 229-235.
21. Castanys-Munoz E, Alder-Baerens N, Pomorski T, Gamarro F, Castanys S, (2007) A novel ATP-binding cassette transporter from Leishmania is involved in transport of phosphatidylcholine analogues and resistance to alkyl-phospholipids. Mol Microbiol 64: 1141-1153.
22. BoseDasgupta S, Ganguly A, Roy A, Mukherjee T, Majumder HK, (2008) A novel ATP-binding cassette transporter, ABCG6 is involved in chemoresistance of Leishmania. Mol Biochem Parasitol 158: 176-188.
23. Castanys-Munoz E, Perez-Victoria JM, Gamarro F, Castanys S, (2008) Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement. Antimicrob Agents Chemother 52: 3573-3579.
24. Perez-Victoria JM, Perez-Victoria FJ, Parodi-Talice A, Jimenez IA, Ravelo AG, et al. (2001) Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob Agents Chemother 45: 2468-2474.
25. Seifert K, Matu S, Javier Perez-Victoria F, Castanys S, Gamarro F, et al. (2003) Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents 22: 380-387.
26. Choudhury K, Zander D, Kube M, Reinhardt R, Clos J, (2008) Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII. Int J Parasitol 38: 1411-1423.
27. Moreira W, Leprohon P, Ouellette M, (2011) Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania. Cell Death Dis 2: e201.
28. Ouellette M, Fase-Fowler F, Borst P, (1990) The amplified H circle of methotrexate-resistant Leishmania tarentolae contains a novel P-glycoprotein gene. Embo J 9: 1027-1033.
29. Papadopoulou B, Roy G, Ouellette M, (1992) A novel antifolate resistance gene on the amplified H circle of Leishmania. Embo J 11: 3601-3608.
30. Sambrook J, Fritsch EF, Maniatis T, (1989) Molecular Cloning: a Laboratory Manual New York Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
31. El Fadili A, Kundig C, Ouellette M, (2002) Characterization of the folylpolyglutamate synthetase gene and polyglutamylation of folates in the protozoan parasite Leishmania. Mol Biochem Parasitol 124: 63-71.
32. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR, (1989) Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77: 61-68.
33. Moreira W, Leblanc E, Ouellette M, (2009) The role of reduced pterins in resistance to reactive oxygen and nitrogen intermediates in the protozoan parasite Leishmania. Free Radic Biol Med 46: 367-375.
34. Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, et al. (2005) The genome of the kinetoplastid parasite, Leishmania major. Science 309: 436-442.
35. Aslett M, Aurrecoechea C, Berriman M, Brestelli J, Brunk BP, et al. (2010) TriTrypDB: a functional genomic resource for the Trypanosomatidae. Nucleic Acids Res 38: D457-462.
36. Li H, Durbin R, (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754-1760.
37. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078-2079.
38. Lassmann T, Hayashizaki Y, Daub CO, (2011) SAMStat: monitoring biases in next generation sequencing data. Bioinformatics 27: 130-131.
39. Koressaar T, Remm M, (2007) Enhancements and modifications of primer design program Primer3. Bioinformatics 23: 1289-1291.
40. Beverley SM, (1991) Gene amplification in Leishmania. Annu Rev Microbiol 45: 417-444.
41. Borst P, Ouellette M, (1995) New mechanisms of drug resistance in parasitic protozoa. Annu Rev Microbiol 49: 427-460.
42. Cruz AK, Titus R, Beverley SM, (1993) Plasticity in chromosome number and testing of essential genes in Leishmania by targeting. Proc Natl Acad Sci U S A 90: 1599-1603.
43. Dumas C, Ouellette M, Tovar J, Cunningham ML, Fairlamb AH, et al. (1997) Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. Embo J 16: 2590-2598.
44. Mottram JC, McCready BP, Brown KG, Grant KM, (1996) Gene disruptions indicate an essential function for the LmmCRK1 cdc2-related kinase of Leishmania mexicana. Mol Microbiol 22: 573-583.
45. Mukherjee A, Roy G, Guimond C, Ouellette M, (2009) The gamma-glutamylcysteine synthetase gene of Leishmania is essential and involved in response to oxidants. Mol Microbiol 74: 914-927.
46. Neary JT, Diven WF, (1970) Purification, properties, and a possible mechanism for pyridoxal kinase from bovine brain. J Biol Chem 245: 5585-5593.
47. Newman JA, Das SK, Sedelnikova SE, Rice DW, (2006) Cloning, purification and preliminary crystallographic analysis of a putative pyridoxal kinase from Bacillus subtilis. Acta Crystallogr Sect F Struct Biol Cryst Commun 62: 1006-1009.
48. Scott TC, Phillips MA, (1997) Characterization of Trypanosoma brucei pyridoxal kinase: purification, gene isolation and expression in Escherichia coli. Mol Biochem Parasitol 88: 1-11.
49. Rakotomanga M, Blanc S, Gaudin K, Chaminade P, Loiseau PM, (2007) Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob Agents Chemother 51: 1425-1430.
50. She QB, Hayakawa T, Tsuge H, (1995) Alteration in the phosphatidylcholine biosynthesis of rat liver microsomes caused by vitamin B6 deficiency. Biosci Biotechnol Biochem 59: 163-167.
51. Sanchez CP, Sidrauski C, Freire SM, Gonzalez NS, Algranati ID, (1995) Ornithine decarboxylase from Leishmania mexicana promastigotes: interaction with pyridoxal 5′-phosphate and alpha-difluoromethylornithine. Biochem Biophys Res Commun 212: 396-403.
52. Thotala D, Chetyrkin S, Hudson B, Hallahan D, Voziyan P, et al. (2009) Pyridoxamine protects intestinal epithelium from ionizing radiation-induced apoptosis. Free Radic Biol Med 47: 779-785.
53. Lee HH, Molla MN, Cantor CR, Collins JJ, (2010) Bacterial charity work leads to population-wide resistance. Nature 467: 82-85.
54. Cui L, Isii T, Fukuda M, Ochiai T, Neoh HM, et al. (2010) An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother 54: 5222-5233.
55. Feng J, Lupien A, Gingras H, Wasserscheid J, Dewar K, et al. (2009) Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res 19: 1214-1223.
56. Howden BP, Stinear TP, Allen DL, Johnson PD, Ward PB, et al. (2008) Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob Agents Chemother 52: 3755-3762.
57. Lescat M, Calteau A, Hoede C, Barbe V, Touchon M, et al. (2009) A module located at a chromosomal integration hot spot is responsible for the multidrug resistance of a reference strain from Escherichia coli clonal group A. Antimicrob Agents Chemother 53: 2283-2288.
58. Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de Lencastre H, et al. (2007) Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A 104: 9451-9456.
59. Hunt P, Martinelli A, Modrzynska K, Borges S, Creasey A, et al. (2010) Experimental evolution, genetic analysis and genome re-sequencing reveal the mutation conferring artemisinin resistance in an isogenic lineage of malaria parasites. BMC Genomics 11: 499.
60. Martinelli A, Henriques G, Cravo P, Hunt P, (2011) Whole genome re-sequencing identifies a mutation in an ABC transporter (mdr2) in a Plasmodium chabaudi clone with altered susceptibility to antifolate drugs. Int J Parasitol 41: 165-171.
61. Chiang DY, Getz G, Jaffe DB, O'Kelly MJ, Zhao X, et al. (2009) High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods 6: 99-103.
62. Quackenbush J, (2002) Microarray data normalization and transformation. Nat Genet 32 (Suppl): 496-501.
63. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, et al. (2009) Circos: an information aesthetic for comparative genomics. Genome Res 19: 1639-1645.